Menu Search
Equities

Paxman AB (publ)

PAX:STO

Paxman AB (publ)

Actions
Health CareMedical Equipment and Services
  • Price (SEK)70.40
  • Today's Change-0.600 / -0.85%
  • Shares traded10.79k
  • 1 Year change+170.77%
  • Beta1.0377
Data delayed at least 15 minutes, as of Nov 12 2024 17:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in SEKIncome statement in SEKView more

Year on year Paxman AB (publ) grew revenues 43.99% from 145.92m to 210.12m. In addition the company has reduced the cost of goods sold, selling, general and administrative expenses and debt expenses (all as a percent of sales). The company reported positive net income, improving from a loss of 10.32m to a profit of 8.33m.
Gross margin70.27%
Net profit margin11.99%
Operating margin12.85%
Return on assets15.66%
Return on equity21.77%
Return on investment20.74%
More ▼

Cash flow in SEKView more

In 2023, cash reserves at Paxman AB (publ) fell by 13.11m. However, the company earned 15.63m from its operations for a Cash Flow Margin of 7.44%. In addition the company used 25.33m on investing activities and also paid 3.41m in financing cash flows.
Cash flow per share2.46
Price/Cash flow per share28.76
Book value per share7.67
Tangible book value per share5.71
More ▼

Balance sheet in SEKView more

Paxman AB (publ) has a Debt to Total Capital ratio of 8.38%, a higher figure than the previous year's 3.14%.
Current ratio2.66
Quick ratio1.98
Total debt/total equity0.0914
Total debt/total capital0.0838
More ▼

Growth rates in SEK

Year on year, growth in earnings per share excluding extraordinary items increased 180.40%.
EPS growth(5 years)--
EPS (TTM) vs
TTM 1 year ago		1,226.95
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.